Skip to main content

Table 2 Relative preference values and preference weights of the pooled and separate surveys

From: Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts

 

Pooled data

 

Ethiopia

 

Switzerland

 

Benefit or harm outcomes related to statins

Coefficient (95% CI) Pairs = 34,320

Preference weight (95% CI)

Coefficient (95% CI (Pairs = 15,600)

Preference weight (95% CI)

Coefficient (95% CI) (Pairs = 18,720)

Preference weight (95% CI)

Severe stroke

6.1 (5.8–6.4)

1.00 (0.997–1.00)b

5.3 (4.9–5.7)

0.999 (0.996–1.00) b

7.4 (6.9–7.9)

1.00 (0.997–1.00)b

Severe MI

4.6 (4.3–4.8)

0.913 (0.889–0.942)

4.0 (3.7–4.3)

0.903 (0.864–0.941)

5.6 (5.2–6.0)

0.869 (0.848–0.921)

Cancera

3.9 (3.7–4.1)

0.846 (0.829–0.855)

3.6 (3.3–3.9)

0.848 (0.821–0.862)

4.4 (4.0–4.7)

0.859 (0.843–0.880)

Moderate stroke

3.1 (2.9–3.3)

0.735 (0.671–0.802)

2.7 (2.4–3.0)

0.686 (0.600–0.783)

3.8 (3.4–4.6)

0.766 (0.644–0.818)

Moderate MI

2.6 (2.4–2.8)

0.664 (0.611–0.715)

2.1 (1.8–2.4)

0.589 (0.517–0.661)

3.2 (2.9–3.5)

0.645 (0.553–0.692)

Heart failure

2.3 (2.1–2.5)

0.591 (0.534–0.647)

2.5 (2.3–2.8)

0.642 (0.593–0.775)

2.2 (1.9–2.5)

0.576 (0.513–0.655)

Type 2 idabetesa

1.7 (1.5–1.9)

0.470 (0.452–0.501)

1.9 (1.6–2.2)

0.557 (0.537–0.608)

1.5 (1.3–1.8)

0.378 (0.347–0.424)

Liver injurya

1.4 (1.2–1.5)

0.431 (0.345–0.475)

1.3 (1.0–1.5)

0.382 (0.300–0.489)

1.4 (1.2–1.7)

0.461 (0.350–0.531)

Unstable angina

1.0 (0.8–1.2)

0.236 (0.205–0.257)

0.8 (0.6–1.1)

0.255 (0.230–0.302)

1.3 (1.0–1.5)

0.285 (0.247–0.323)

Acute kidney failurea

0.9 (0.7–1.1)

0.236 (0.215–0.252)

1.2 (0.9–1.4)

0.283 (0.239–0.296)

0.7 (0.4–0.9)

0.262 (0.242–0.293)

Myopathya

0.6 (0.4–0.8)

0.230 (0.228–0.238)

0.6 (0.4–0.8)

0.256 (0.254–0.258)

0.6 (0.4–0.8)

0.255 (0.253–0.256)

Nausea/headachea

0.2 (0.0–0.4)

0.060 (0.034–0.094)

0.2 (−0.1–0.5)

0.093 (0.060–0.139)

0.2 (0.0–0.5)

0.065 (0.035–0.105)

Treatment discontinuationa,c

0.0

0.090 (0.023–0.123)

0.00

0.020 (0.00–0.090)

0.0

0.085 (0.002–0.141)

  1. aHarms related to statins
  2. bOne-sided test since 1 is the ceiling values for a probability scale
  3. cThere could be more harms that are associated with taking statins, including cognitive or sleep disorders problems, which were not reported in our study. Unless stated distinctly by their names, these harms are included in our study with a collective term ‘side effects’ in the BWS procedure for the sake of clarity to the participants, but reported as ‘treatment discontinuation due to side-effects’ here up in the table and throughout the article
  4. Coefficient Log-scaled coefficients from conditional logit model
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us